Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: A randomized, double-blind, placebo-controlled clinical trial

Journal of Clinical Psychopharmacology

Volumn 33, Issue 1, 2013, Pages 45-54

  Durell, Todd M ^a   Adler, Lenard A ^b   Williams, Dave W ^c   Deldar, Ahmed ^a   McGough, James J ^d   Glaser, Paul E ^e   Rubin, Richard L ^f   Pigott, Teresa A ^g   Sarkis, Elias H ^h   Fox, Bethany K ^a  

^a ELI LILLY AND COMPANY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PharmaNet/i3   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f Vermont Clinical Study Center   (United States)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^h Sarkis Family Psychiatry   (United States)

Author keywords

atomoxetine; attention deficit hyperactivity disorder; young adults

Indexed keywords

ATOMOXETINE;

ADULT; ADULT ADHD QUALITY OF LIFE 29; ANXIETY; APPETITE DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR RATING INVENTORY OF EXECUTIVE FUNCTION ADULT VERSION SELF REPORT; CLINICAL GLOBAL IMPRESSION ADHD SEVERITY; CONNERS ADULT ADHD RATING SCALE; CONNERS ADULT ADHD RATING SCALE SELF REPORT; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRIVING ABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DYSPEPSIA; FEMALE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; OUTCOME ASSESSMENT; PATIENT GLOBAL IMPRESSION IMPROVEMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOCIAL ADAPTATION; SUBSTANCE ABUSE; TREATMENT OUTCOME; XEROSTOMIA;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; ANALYSIS OF VARIANCE; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOUBLE-BLIND METHOD; EXECUTIVE FUNCTION; HUMANS; LEAST-SQUARES ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPYLAMINES; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PUERTO RICO; QUALITY OF LIFE; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84873096668     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31827d8a23     Document Type: Article

References (42)

1. Barkley RA, Murphy KR, Fischer M. ADHD in Adults: What The Science Says. New York, NY: The Guilford Press; 2008.
2. Lara C, Fayyad J, de Graaf R, et al. Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative. Biol Psychiatry. 2009;65(1):46-54.
3. Mick E, Faraone SV, Biederman J. Age-dependent expression of attention-deficit/hyperactivity disorder symptoms. Psychiatr Clin North Am. 2004;27(2):215-224.
4. Biederman J, Monuteaux MC, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med. 2006;36(2):167-179.
5. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002; 63(suppl 12):10-15.
6. Biederman J, Petty CR, Fried R, et al. Educational and occupational underattainment in adults with attention-deficit/hyperactivity disorder: a controlled study. J Clin Psychiatry. 2008;69(8):1217-1222.
7. Galéra C, Melchior M, Chastang JF, et al. Childhood and adolescent hyperactivity-inattention symptoms and academic achievement 8 years later: the GAZEL Youth study. Psychol Med. 2009;39(11):1895-1906.
8. Breyer JL, Botzet AM, Winters KC, et al. Young adult gambling behaviors and their relationship with the persistence of ADHD. J Gambl Stud. 2009;25(2):227-238.
9. Fischer M, Barkley RA, Smallish L, et al. Hyperactive children as young adults: driving abilities, safe driving behavior, and adverse driving outcomes. Accid Anal Prev. 2007;39(1):94-105.
10. Fried R, Monuteaux MC, Hughes S, et al. Driving deficits in young adults with attention-deficit/hyperactivity disorder. J ADHD Relat Disord. 2009;1(1):49-57.
11. Biederman J, Petty CR, Wilens TE, et al. Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry. 2008;165(1):107-115.
12. Pomerleau OF, Downey KK, Stelson FW, et al. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse. 1995;7(3):373-378.
13. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use and diversion of prescription stimulant medication. J Psychoactive Drugs. 2006;38(1): 43-56.
14. Rabiner DL, Anastopoulos AD, Costello EJ, et al. The misuse and diversion of prescribed ADHD medications by college students. J Atten Disord. 2009;13(2):144-153.
15. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(1):21-31.
16. Durell T, Adler L, Wilens T, et al. Atomoxetine treatment for ADHD: younger adults compared with older adults. J Atten Disord. 2010;13:401-406.
17. Kessler RC, Adler LA, Gruber MJ, et al. Validity of the World Health Organization Adult ADHD Self-report Scale (ASRS) Screener in a representative sample of health plan members. Int J Methods Psychiatr Res. 2007;16(2):52-65.
18. Adler L, Liebowitz M, Kronenberger W, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety. 2009;26(3):212-221.
19. Adler L, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult ADHD: a six-month, double-blind trial. J Clin Psychopharmacol. 2009;29:44-50.
20. Strattera (Atomoxetine) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2011.
21. Adler LA, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004; 27(2):187-201.
22. Adler LA, Spencer T, Faraone SV et al. Training raters to assess adult ADHD: reliability of ratings. J Atten Disord. 2005;8:121-126.
23. Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales (CAARS). North Tonawanda, NY: Multi-Health Systems Inc; 1999.
24. Westfall P. Gatekeeping strategies for testing primary and secondary endpoints. Presented at the Drug Information Association Meeting; Savannah, GA; March 12; 2001.
25. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised 1976. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch 217-222-313-331; 1976.
26. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
27. Sobell L, Sobell M. Timeline follow back: a technique for assessing self-reported alcohol consumption. In: Zitten RZ, Allen JP, eds. Measuring Alcohol Consumption: Psychological and Biological Methods. Totowa, NJ: The Humana Press Inc; 1992:41-72.
28. Sobell LC, Sobell MB. Alcohol Timeline Followback User's Manual. Toronto, CAN: Addiction Research Foundation; 1995.
29. Fagerström KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerström Tolerance Questionnaire. J Behav Med. 1989;12(2):159-182.
30. Bosc M, Dubini A, Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur Neuropsychopharmacol. 1997;7(suppl 1):57-70.
31. Mahone EM, Cirino PT, Cutting LE, et al. Validity of the behavior rating inventory of executive function in children with ADHD and/or Tourette syndrome. Arch Clin Neuropsychol. 2002;17(7):643-662.
32. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-545.
33. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112-120.
34. Adler LA, Spencer TJ, Milton DR, et al. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/ hyperactivity disorder: an interim analysis. J Clin Psychiatry. 2005;66(3):294-299.
35. Chao CY, Gau SS, Mao WC, et al. Relationship of attention-deficit- hyperactivity disorder symptoms, depressive/anxiety symptoms, and life quality in young men. Psychiatry Clin Neurosci. 2008;62(4):42.
36. Surman CB, Adamson JJ, Petty C, et al. Association between attention-deficit/hyperactivity disorder and sleep impairment in adulthood: evidence from a large controlled study. J Clin Psychiatry. 2009;70(11):1523- 1529.
37. Sandra Kooij JJ, Marije Boonstra AM, Swinkels SH, et al. Reliability, validity, and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients. J Atten Disord. 2008;11(4):445-458.
38. US Census Bureau, 2006-2008 American Community Survey. Available at: http://factfinder.census.gov/servlet/DatasetMainPageServlet?- program=ACS. Accessed August10, 2010.
39. Durell TM, Pumariega AJ, Rothe EM, et al. Effects of open-label atomoxetine on African-American and Caucasian pediatric outpatients with attention-deficit/hyperactivity disorder. Ann Clin Psychiatry. 2009;21(1):26-37.
40. Tamayo JM, Pumariega A, Rothe EM, et al. Latino versus Caucasian response to atomoxetine in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2008;18(1):44-53.
41. Wendler D, Kington R, Madans J, et al. Are racial and ethnic minorities less willing to participate in health research? PLoS Med. 2006;3(2):e19.
42. Khan A, Kolts RL, Rapaport MH, et al. Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychol Med. 2005;35:743-749.